Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system
Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals Validated system provides reliable, consistent...
CEPI and Samsung Biologics collaborate to strengthen outbreak-ready vaccine production and global access
OSLO, Norway and INCHEON, South Korea, Feb. 3, 2026 /PRNewswire/ -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today...
Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating
Ranked in the top one percent among more than 150,000 companies assessed globally Recognized for strengthened sustainability management across all four assessment categories INCHEON, South Korea, Jan. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX:...
Samsung Biologics reports fourth quarter and fiscal year 2025 financial results
Recorded Q4'25 revenue of KRW 1,286 billion and FY'25 revenue of KRW 4,557 billion Maintained momentum through consistent operational performance and robust client demand Strengthened foundation for long-term growth through expanded manufacturing...
Samsung Biologics recognized as a global leader in water security
Company receives the highest Water Security rating in two years into participation Recognized for exceptional leadership in environmental stewardship INCHEON, South Korea, Dec. 11, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading...
Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO
Spin-off finalized within five months following board resolution Proposal approved in shareholders' meeting with 99.9% support Company to reaffirm its identity as a pure-play CDMO INCHEON, South Korea, Nov. 3, 2025 /PRNewswire/ -- Samsung Biologics...
Samsung Biologics reports third quarter 2025 financial results
Recorded Q3'25 consolidated revenue of KRW 1,660.2 billion Recorded Q3'25 consolidated operating profit of KRW 728.8 billion Delivered consistent performance through stable capacity ramp-up and strengthened global partnerships INCHEON, South Korea,...
Samsung Biologics launches drug screening services, Samsung Organoids
Samsung Organoids to provide data-driven analysis of candidate molecules Samsung Biologics expands service scope to include preclinical research INCHEON, South Korea, June 16, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading...
Samsung Biologics reports first quarter 2025 financial results
Recorded Q1'25 consolidated revenue of KRW 1.3 trillion Recorded Q1'25 consolidated operating profit of KRW 486.7 billion Company expected to maintain steady growth momentum in 2025 driven by enhanced operational efficiency and diverse service...
Samsung Biologics recognized for leadership band in water security
- Company receives leadership status and A- rating for efficient water resources management - Recognition reflects Samsung Biologics' commitment to water security and implementing sustainable practices across operations INCHEON, South Korea, Feb....